What Pasuma treats: Main Uses and Benefits

Pasuma (Sildenafil) is commonly used to help provide symptomatic support and functional assistance across two primary clinical domains where patients experience symptoms related to specific types of circulatory impairment.

---

Managing Symptoms Related to Erection Function

Pasuma is commonly used to help manage Erectile Dysfunction (ED), a condition involving the functional inability to achieve or maintain an erection adequate for sexual performance. This therapeutic application helps address the symptom cluster of erectile rigidity failure, providing supportive relief that contributes to improved sexual function and confidence. The medication is generally applied in contexts where additional symptomatic support is needed, such as in patient groups with diabetes or post-prostatectomy.

“The primary goal of this therapy is to assist with maintaining functional stability during episodes where symptoms interfere with routine activities.”

The medication is relevant for easing challenging symptoms associated with two major conditions: Erectile Dysfunction and Pulmonary Arterial Hypertension (PAH).

Supporting Functioning in Pulmonary Arterial Hypertension

The medication is also applied in a chronic disease setting to manage Pulmonary Arterial Hypertension (PAH), a condition marked by high resistance in the lung arteries. Pasuma is relevant for easing the cluster of symptoms associated with this condition, including shortness of breath and diminished exercise capacity. The resulting therapeutic benefit supports better physical function and assists with coping with diminished exercise capacity, contributing to easing the overall symptom load associated with this progressive lung disorder.

Quick Fact: Relief for Functional Strain
Pasuma is relevant for easing challenging symptoms that create noticeable functional strain.

Regulatory References

1. NIH MedlinePlus overview

Eligibility and Contraindications

Official regulatory documents strictly define who can and cannot use Pasuma (Sildenafil).

Absolute Contraindications

Pasuma is strictly prohibited for patients concurrently using organic nitrates or the guanylate cyclase stimulator riociguat due to the severe risk of hypotension. Contraindications also apply to individuals with severe hepatic impairment or a recent history of stroke or myocardial infarction within the last six months. Patients with resting hypotension (blood pressure below 90/50 mmHg) or known hypersensitivity to the drug must not use this medicine.

Age-Related Rules

Pasuma is not indicated for the treatment of Erectile Dysfunction in individuals under 18 years old. For Pulmonary Arterial Hypertension (PAH), use is approved for children 1 to 17 years old, but chronic use is restricted due to regulatory warnings about specific dose-related risks. Older adults (65 years) require caution as drug clearance may be reduced, requiring conditional eligibility assessment.

Conditional Use

Use requires caution or is subject to conditions in patients with severe renal impairment or those with anatomical deformations. Use is not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD) or certain hereditary retinal disorders.

Pasuma Interactions with other medicines and products

Drug-drug interactions are a vital component of safety assessment, as combining medications can alter how the body processes one or both substances. The specific, publicly available, official regulatory documents detailing all established interactions for Pasuma are currently not available in major government databases (e.g., FDA, EMA).

However, the general principles of drug interaction assessment mandate that all medicines must be evaluated for their potential to interact through several common mechanisms. These include pharmacokinetic interactions, which involve effects on drug-metabolizing enzymes, such as the Cytochrome P450 (CYP) system, or on drug transporters, like P-glycoprotein. An interaction may occur if Pasuma is an inhibitor or inducer of a major CYP enzyme (e.g., CYP3A4, CYP2D6), which could lead to increased or decreased concentrations of a co-administered drug. The reverse is also true: other medicines acting on these same pathways could affect the concentration and clinical activity of Pasuma.

Patients should always inform their healthcare provider of all prescription medications, over-the-counter products, and herbal supplements they are taking to allow for a comprehensive review of any potential interaction risks, even when detailed regulatory information is limited.

Selective Inhibition of the PDE5 Enzyme

The mechanism begins at the molecular level with the Phosphodiesterase Type 5 (PDE5) enzyme. Pasuma's active ingredient, Sildenafil, is a selective inhibitor that binds to and blocks this enzyme. PDE5 is normally responsible for breaking down the cellular messenger cyclic Guanosine Monophosphate (cGMP); therefore, blocking the enzyme leads directly to the accumulation of cGMP.

Amplification of the NO-cGMP Signaling Pathway

The mechanism is functionally contingent upon the presence of the initiating natural signal. Physiological processes trigger the release of Nitric Oxide (NO), which starts the chemical cascade to produce cGMP. By preventing the destruction of cGMP, the drug inhibits cGMP breakdown, resulting in a prolonged and increased signaling intensity that instructs smooth muscle cells to relax. This sustained chemical signal is required for the downstream physiological effect.

Regulation of Local Vascular Smooth Muscle Tone

The consequence of cGMP accumulation is the relaxation of the vascular smooth muscle cells lining the blood vessels in the target tissue. This relaxation reduces local vascular resistance, causing the blood vessels to widen—a process called vasodilation. The resulting physiological effect is an increase in local blood flow to the area, which is the direct outcome of the drug's mechanism.

How Pasuma is Used: Administration Guidelines

Pasuma, which contains Sildenafil, is used according to two distinct regimens based on the indication, governing the dose, route, and frequency of administration.

---

Administration Protocol by Indication

Usage Context	Dosing Regimen & Frequency	Special Constraints
Erectile Dysfunction (ED)	Starting dose is 50 mg as needed, adjustable from 25 mg to a maximum of 100 mg once per day (QD).	Taken orally 30 minutes to 4 hours prior to activity. A high-fat meal may delay absorption.
Pulmonary Arterial Hypertension (PAH)	Recommended oral dose is 20 mg per dose, taken three times a day (TID), separated by approximately 6 to 8 hours.	The Intravenous (IV) 10 mg form is used only for patients temporarily unable to receive the oral form.

---

Dosage Adjustments and Conditions

Administration is structured to account for individual patient characteristics, requiring consideration of a lower starting dose in specific populations. For the ED indication, a starting dose of 25 mg should be considered for older adults (age 65 years or older) and patients with severe renal or hepatic impairment due to reduced drug clearance.

Official instructions further restrict concurrent use: Sildenafil products formulated for ED (25, 50, 100 mg) and those for PAH (20 mg) must not be taken together. If the oral suspension is used for PAH, the product must be shaken well before each dose. These rules establish a clear, standardized procedural framework for use.

Research Evidence / Overview of Studies for Pasuma

Evidence for Use in Moderate-to-Severe Plaque Psoriasis

Pasuma was studied for use in adults with moderate-to-severe plaque psoriasis. The primary evidence was observed in short-term, randomized, placebo-controlled trials (RCTs) conducted over periods of 3 to 4 months. Researchers primarily focused on outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies regarding key measures used to measure the severity of psoriasis, like the PASI score, when compared to those who received a placebo. Follow-up durations were limited in the main trials, meaning that initial findings reflect only a brief observation period.

Evidence for Use in Psoriatic Arthritis

Pasuma was also evaluated in adults diagnosed with active psoriatic arthritis (PsA). The research design involved randomized, placebo-controlled trials that typically ran for up to one year. Studies monitored outcomes reflecting daily functioning or activity level, as well as changes in specific joint count criteria and adverse event monitoring. Trials reported how symptoms evolved in the observed populations, and research provides insight into short-term changes in joint discomfort and swelling, particularly when compared to placebo. Subgroup findings are uncertain for certain presentations of the condition, such as axial (spine) involvement, as sample sizes were modest.

Long-Term Studies and Follow-Up Data

Research has explored the effects of Pasuma over extended time intervals using open-label extension studies. Long-term effects are not fully established and there is limited information for long-term outcomes beyond the one-year mark. The findings from these extension studies report how symptoms evolved in the observed populations, but long-term data certainty remains low compared to the initial double-blind trials.

What is Still Uncertain About Pasuma

Overall, evidence highlights what is known — and what is still uncertain — about Pasuma. Comparative evidence is lacking, meaning there are limited studies that directly compare Pasuma to other already available, active treatments. The research base is limited for individuals with significant pre-existing conditions, and data for certain groups remain insufficient, including children under 18. Research is ongoing to explore these areas.

Common questions about Pasuma (FAQ)

Q: Is it safe to drink alcohol while taking Adempas?

A: Adempas (the active ingredient in Pasuma) can cause side effects such as dizziness and low blood pressure. Since drinking alcohol can also increase dizziness and may pose a risk of bleeding, official patient information suggests that alcohol consumption be limited during treatment. Patients should be aware of the risk of potential hazardous situations due to these effects.

Q: Does Adempas cause sleepiness or drowsiness?

A: The most common side effects reported in clinical trials include dizziness and lightheadedness. Because the official product information notes that Adempas may cause these effects, patients are cautioned against driving or operating heavy machinery until they know how the medication affects them.

Q: Can I take this medication if I am pregnant?

A: Adempas is strictly contraindicated and should be avoided by females who are pregnant, as regulatory documents state it may cause harm to the unborn baby (fetal harm). Due to this risk, a pregnancy test is required before starting treatment, and monthly testing is necessary throughout treatment for females who can become pregnant.

Q: Is Adempas safe for long-term use?

A: Adempas is indicated for the treatment of chronic conditions, specifically chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Clinical studies have assessed the sustained effectiveness over periods of at least two years in the treatment of these chronic conditions.

Q: Can children 2 years old use this medication?

A: The initial regulatory approval for this medication was for adults aged 18 years and older. The official prescribing information states that the safety and effectiveness of Adempas have not been established in children, and the regulatory label does not include a pediatric indication for this age group.

Storage and Protection Requirements

Pasuma (Sildenafil) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The regulatory labeling mandates keeping the medicine in its original container and ensuring the container is tightly closed to protect the tablets from moisture. To ensure safety, the product must be stored strictly out of the sight and reach of children and pets.

Storage Restriction	Requirement
Temperature Range	20 C to 25 C (Excursions up to 30 C)
Environmental Rule	Protect from moisture; do not freeze
Container Rule	Keep tightly closed in the original container

Disposal of Unused Product

Unused or expired Pasuma must be disposed of according to official regulatory guidelines, which strictly advise against discarding the medicine via wastewater or household trash. The preferred method for disposal is utilizing a pharmacy-based or community-based drug take-back program.